Resting Heart Rate in Cardiovascular Disease

• Published in: Journal of the American College of Cardiology 2007-08, Vol.50 (9), p.823-830
• Main Authors: Fox, Kim, MD, FESC, Borer, Jeffrey S., MD, FACC, Camm, A. John, MD, FESC, FACC, Danchin, Nicolas, MD, FESC, Ferrari, Roberto, MD, FESC, Lopez Sendon, Jose L., MD, FESC, FACC, Steg, Philippe Gabriel, MD, FESC, FACC, Tardif, Jean-Claude, MD, FACC, FRCPC, Tavazzi, Luigi, MD, FESC, FACC, Tendera, Michal, MD, FESC, FACC
• Format: Article
• Language: English
• Subjects: Adrenergic beta-Antagonists - pharmacology; Animals; Arrhythmias, Cardiac - drug therapy; Arrhythmias, Cardiac - physiopathology; Biological and medical sciences; Calcium Channel Blockers - pharmacology; Carbazoles - therapeutic use; Cardiac Output, Low - mortality; Cardiology; Cardiology. Vascular system; Cardiovascular; Cardiovascular disease; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - mortality; Cardiovascular Diseases - physiopathology; Coronary Artery Disease - drug therapy; Coronary Artery Disease - physiopathology; Coronary Disease - mortality; Coronary Disease - physiopathology; Coronary vessels; Exercise Test; Heart attacks; Heart Rate - drug effects; Heart Rate - physiology; Humans; Internal Medicine; Medical sciences; Metoprolol - therapeutic use; Mortality; Multivariate Analysis; Myocardial Infarction - mortality; Myocardial Ischemia - physiopathology; Older people; Prognosis; Propanolamines - therapeutic use; Risk Assessment; Risk Factors; Timolol - therapeutic use; Ventricular Dysfunction, Left - physiopathology
• ISSN: 0735-1097; 1558-3597
• DOI: 10.1016/j.jacc.2007.04.079

Resting Heart Rate in Cardiovascular Disease Kim Fox, Jeffrey S. Borer, A. John Camm, Nicolas Danchin, Roberto Ferrari, Jose L. Lopez Sendon, Philippe Gabriel Steg, Jean-Claude Tardif, Luigi Tavazzi, Michal Tendera, for the Heart Rate Working Group Recent large epidemiologic studies have confirmed earlier studies that showed resting heart rate (HR) to be an independent predictor of cardiovascular and all-cause mortality in men and women with and without cardiovascular disease. Clinical trial data suggest that HR reduction is an important mechanism of benefit of beta-blockers and other HR lowering drugs. Pathophysiological studies indicate that a relatively high HR has direct detrimental effects on the progression of coronary atherosclerosis, on the occurrence of myocardial ischemia and ventricular arrhythmias, and on left ventricular function. Studies have found a continuous increase in risk with HR above 60 beats/min.